Adirondack Trust Company’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Adirondack Trust Company’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-55	Closed	-$9.11K	–	496
2023 Q2	$9.11K	Hold	55	–	–	﹤0.01%	343
2023 Q1	$5K	Hold	55	–	–	﹤0.01%	400
2022 Q4	$2.09K	Hold	55	–	–	﹤0.01%	444
2022 Q3	$1K	Hold	55	–	–	﹤0.01%	473
2022 Q2	$2K	Hold	55	–	–	﹤0.01%	430
2022 Q1	$2K	Hold	55	–	–	﹤0.01%	411
2021 Q4	$1K	Buy	+55	New	+$4.26K	﹤0.01%	420

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Adirondack Trust Company's RETA Position: Q3 2023 in Review

Adirondack Trust Company sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 55 shares — an estimated $9.11K sold.

Adirondack Trust Company first reported a position in RETA in Q4 2021 and held it in 7 quarters. The position peaked at $9.11K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Adirondack Trust Company reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Adirondack Trust Company sold 55 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $9.11K.
Adirondack Trust Company first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2021 and held it in 7 quarters.
Adirondack Trust Company's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $9.11K in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Adirondack Trust Company's 13F filing for Q3 2023, filed 31 Oct 2023.